Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex

Marx, Jana; Welte, René; Gasperetti, Tiziana; Moser, Patrizia; Beer, Ronny; Ortler, Martin; Jeske, Martina; Stern, R.G.; Pomaroli, A; Joannidis, Michael; Bellmann, Romuald

doi:10.1128/aac.00275-20

Cited by 6 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In brain samples taken from our study population we had measured anidulafungin concentrations of 0.21 -2.34 µg/g and micafungin concentrations of 0.18 -2.88 µg/g. These data have been reported previously together with concentrations in cerebrospinal fluid of critically ill patients, which were even lower than brain concentrations (8). Preclinical studies revealed anidulafungin and micafungin tissue concentrations and distribution comparable with our findings, but in rodents, highest concentrations were measured in lung (11,(14)(15)(16).…”

Section: Invasive Candidiasis May Affect Various Tissues Causing Deep-seated Candidiasissupporting

confidence: 92%

“…Anidulafungin and micafungin concentrations were quantified in thyroid, lung, myocardium, spleen, liver, kidney, pancreas, and skeletal muscle. The echinocandins were extracted and quantified as described previously for brain (8). In brief, 0.2 g of tissue were homogenized with acetonitrile and methanol and concentrations were measured with high-performance liquid chromatography and UV detection (8,9).…”

mentioning

confidence: 99%

“…The echinocandins were extracted and quantified as described previously for brain (8). In brief, 0.2 g of tissue were homogenized with acetonitrile and methanol and concentrations were measured with high-performance liquid chromatography and UV detection (8,9). The external standards consisted of animal tissue spiked with anidulafungin or micafungin.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Human Tissue Distribution of Anidulafungin and Micafungin

Marx

Welte

Gasperetti

et al. 2021

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

Concentrations of anidulafungin and micafungin were determined in eight different tissues obtained during autopsy of four deceased who had been treated with anidulafungin and of seven who had obtained micafungin. The highest amounts were recovered from liver with anidulafungin concentrations of 11.01 – 66.50 μg/g and micafungin levels of 0.36 – 5.53 μg/g (0.65 μg/g 30 days after the last administration). The lowest anidulafungin levels were measured in skeletal muscle, lowest micafungin concentrations in kidney.

show abstract

Section: Invasive Candidiasis May Affect Various Tissues Causing Deep-seated Candidiasissupporting

confidence: 92%

mentioning

confidence: 99%

See 1 more Smart Citation

Human Tissue Distribution of Anidulafungin and Micafungin

Marx

Welte

Gasperetti

et al. 2021

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

show abstract

“…As a result, combination therapy should be utilized in specific settings such as those with (1) high azoleresistance rates [94] (2) in cases with lacking response to monotherapy (3) when the species of Aspergillus is unknown or susceptibility testing is pending (4) or when therapeutic level of voriconazole cannot be reached due to poor metabolism by concurrently administered medication. For CNS infections, combination therapy may be complicated due to concerns about antagonism between voriconazole and LAmB and the poor brain and cerebro-spinal fluid penetration of echinocandins [34,95]. The antimetabolite flucytosine is another option, particularly in combination with LAmB for severe Cryptococcal infections (meningitis, pneumonia), difficult to treat invasive Candida infections, as well as for urogenital infections involving fluconazole-resistant C. glabrata [96].…”

Section: Combination Therapymentioning

confidence: 99%

Treatment of Invasive Aspergillosis: How It’s Going, Where It’s Heading

et al. 2023

View full text Add to dashboard Cite

Despite improvements in treatment and diagnostics over the last two decades, invasive aspergillosis (IA) remains a devastating fungal disease. The number of immunocompromised patients and hence vulnerable hosts increases, which is paralleled by the emergence of a rise in IA cases. Increased frequencies of azole-resistant strains are reported from six continents, presenting a new challenge for the therapeutic management. Treatment options for IA currently consist of three classes of antifungals (azoles, polyenes, echinocandins) with distinctive advantages and shortcomings. Especially in settings of difficult to treat IA, comprising drug tolerance/resistance, limiting drug–drug interactions, and/or severe underlying organ dysfunction, novel approaches are urgently needed. Promising new drugs for the treatment of IA are in late-stage clinical development, including olorofim (a dihydroorotate dehydrogenase inhibitor), fosmanogepix (a Gwt1 enzyme inhibitor), ibrexafungerp (a triterpenoid), opelconazole (an azole optimized for inhalation) and rezafungin (an echinocandin with long half-life time). Further, new insights in the pathophysiology of IA yielding immunotherapy as a potential add-on therapy. Current investigations show encouraging results, so far mostly in preclinical settings. In this review we discuss current treatment strategies, give an outlook on possible new pharmaceutical therapeutic options, and, lastly, provide an overview of the ongoing research in immunotherapy for IA.

show abstract

“…For certain infections, liposomal amphotericin B is preferred, such as when C. auris is isolated from the cerebrospinal fluid and reliable concentrations of echinocandins cannot be attained in that space. 83 …”

Section: Diagnosis and Treatmentmentioning

confidence: 99%

Candida auris in skilled nursing facilities

Yune

Coe

Rao³

et al. 2023

Therapeutic Advances in Infection

View full text Add to dashboard Cite

Candida auris is a fungal organism resistant to several classes of antifungals. Since its identification in 2009, it has gained worldwide attention in healthcare for its virulence and resistance to commonly used antifungal therapeutics. Although its origin and mechanisms of transmission are not fully elucidated, it is widely recognized as a high priority healthcare-associated pathogen. Infection control efforts in skilled nursing facilities have been very challenging due to the tendency of C. auris to persist in the environment and colonize residents. In this narrative review, we discuss the epidemiology and infection prevention of C. auris in skilled nursing facilities. We also identify challenges in the diagnosis and management of both symptomatic infections and asymptomatic colonization.

show abstract

Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex

Cited by 6 publications

References 20 publications

Human Tissue Distribution of Anidulafungin and Micafungin

Human Tissue Distribution of Anidulafungin and Micafungin

Treatment of Invasive Aspergillosis: How It’s Going, Where It’s Heading

Candida auris in skilled nursing facilities

Contact Info

Product

Resources

About